Literature DB >> 21342041

Palliative therapy for osteosarcoma.

Costantino Errani1, Alessandra Longhi, Giuseppe Rossi, Eugenio Rimondi, Alessio Biazzo, Angelo Toscano, Nikolin Alì, Pietro Ruggieri, Marco Alberghini, Piero Picci, Gaetano Bacci, Mario Mercuri.   

Abstract

Despite advances in diagnostic imaging, the evolution of neoadjuvant chemotherapy and the refinements in limb-salvage surgery, the progression-free survival rate remains poor for patients with metastatic, recurrent or unresectable osteosarcoma. Different therapeutic strategies for these subgroups of patients have been employed to control disease and prolong survival. Treatment options are limited and controversial, including systemic and localized therapies. Surgical resection, whenever feasible, is still the standard treatment in advanced osteosarcoma. The role of chemotherapy is unclear while the use of radiotherapy, embolization and thermal ablation is increasing. New therapeutic experimental approaches and novel target therapies are needed to improve the outcome of these subgroups of patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342041     DOI: 10.1586/era.10.172

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  21 in total

1.  The prognostic value of elevated ezrin in patients with osteosarcoma.

Authors:  Deng-Xing Lun; Yong-Cheng Hu; Zhao-Wan Xu; Li-Na Xu; Bin-Wu Wang
Journal:  Tumour Biol       Date:  2013-09-07

2.  Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.

Authors:  Shuier Zheng; Shuhui Zhou; Guanglei Qiao; Qingcheng Yang; Zhichang Zhang; Feng Lin; Daliu Min; Lina Tang; Hongtao Li; Yuanjue Sun; Hui Zhao; Zan Shen; Yang Yao
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma.

Authors:  Wu Yang; He Maolin; Zhao Jinmin; Wang Zhe
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-08       Impact factor: 4.553

4.  Palliative embolisation for advanced bone sarcomas.

Authors:  A F Mavrogenis; G Rossi; G Altimari; T Calabrò; A Angelini; E Palmerini; E Rimondi; P Ruggieri
Journal:  Radiol Med       Date:  2012-08-09       Impact factor: 3.469

5.  Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients.

Authors:  Ayse Durnali; Necati Alkis; Sengul Cangur; Fisun Ardic Yukruk; Ali Inal; Saadet Tokluoglu; Mehmet Metin Seker; Oznur Bal; Tulay Akman; Mevlude Inanc; Abdurrahman Isikdogan; Ayse Demirci; Kaan Helvaci; Berna Oksuzoglu
Journal:  Med Oncol       Date:  2013-06-09       Impact factor: 3.064

6.  Serum C-reactive protein and overall survival of patients with osteosarcoma.

Authors:  Xiaochuan Li; Feng Tian; Fei Wang; Yanfeng Li
Journal:  Tumour Biol       Date:  2015-05-19

Review 7.  [Update on 3D printing in the surgery of musculoskeletal tumors].

Authors:  Mohamed Omar; Martin Schulze; Nico Bruns; Daniel Kotrych; Georg Gosheger; Max Ettinger
Journal:  Unfallchirurg       Date:  2022-03-21       Impact factor: 1.000

Review 8.  A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.

Authors:  Ding Chen; Ye-Jia Zhang; Ke-wei Zhu; Wan-Chun Wang
Journal:  Tumour Biol       Date:  2013-04-16

9.  Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma.

Authors:  Shangzeng Wang; Xiaoya Liu; Zike He; Xinfeng Chen; Wei Li
Journal:  Tumour Biol       Date:  2015-08-18

10.  Palliative embolization for osteosarcoma.

Authors:  Andreas F Mavrogenis; Giuseppe Rossi; Eugenio Rimondi; Teresa Calabrò; Panayiotis J Papagelopoulos; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.